12th March|Commercial Media

IPA appointment sees OptiBiotix pioneer a probiotic future

OptiBiotix Health, a leading life sciences business focused on harnessing the power of the human microbiome, has announced the appointment of its Director of Business Development, Dr. Luis Gosálbez, as the second Chair to the Education and Communications Committee (ECC) of the International Probiotics Association (IPA).

The appointment sees OptiBiotix gain influence throughout the life sciences sector and take a leading role in promoting a greater understanding of probiotic solutions, such as the firm’s innovative Lactobacillus plantarum (LPLDL®) strain.

Dr. Gosálbez commented: “The IPA is an internationally respected organisation currently working with its ECC to become the Global Voice of Probiotics. The IPA allows more than one hundred healthcare and probiotics firms throughout Europe, Asia, Middle East & Africa, Oceania, South and North America, to talk to the future of probiotic health maintenance. The organisation works with government bodies alongside the industry to assist in establishing scientific standards for probiotics, pharmaceutical products and functional foods.”

“My presence on the Committee grants OptiBiotix exclusive access to IPA’s professional scientific network, designed to grow probiotic intelligence and educate consumers and authorities on their proven health benefits. Our end of year meeting in Las Vegas evidenced the IPA’s widespread popularity, with 2018 seeing a 26.6 per cent increase in members including pending membership applications. OptiBiotix and I are delighted to be part of this growing scientific community and look forward to networking with others in the business to pioneer a healthier future.”

Harnessing the microbiome-liver axis to positively impact upon the gut microbiome, OptiBiotix’s lead probiotic strain Lactobacillus plantarum LPLDL®, demonstrates an exceptional capacity to modulate the metabolism of bile acids. This activity is important to bacterial survival in the hostile environment of the intestine, aiding conditions such as high blood pressure and high cholesterol, as well as physiological processes. LPLDL® has in human studies proven to lower total cholesterol levels by 36.7 per cent and offers a natural, scientifically founded alternative with no known side effects.

For further information regarding the work of OptiBiotix and the International Probiotics Association, please visit www.optibiotix.com and www.internationalprobiotics.org